Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-43260295 in Healthy and Atopic Asthmatic Subjects
NCT02243189Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-43260295 in asthma (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Cytokine Levels in Nasal Lavage and Gene Expression in Nasal Scrapings. Started Oct 2014; status: terminated.
02
Drugs
JNJ-43260295
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02243189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243189.